EGFR and colorectal cancer: For molecular-targeted therapies, some reports have shown that ctDNA is useful for evaluation of treatment response and resistance, such as RAS mutation in colorectal cancer or EGFR mutations in lung cancer, known as targeting driver genes [45–48].